Canada Antibody Drug Conjugates Market Size & Outlook
Related Markets
Canada antibody drug conjugates market highlights
- The Canada antibody drug conjugates market generated a revenue of USD 66.4 million in 2021 and is expected to reach USD 401.8 million by 2030.
- The Canada market is expected to grow at a CAGR of 22.1% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Urothelial Cancer & Bladder Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 66.4 million |
| Market revenue in 2030 | USD 401.8 million |
| Growth rate | 22.1% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Urothelial Cancer & Bladder Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Canada accounted for 1.1% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 401.8 million by 2030.
Blood cancer was the largest segment with a revenue share of 66.57% in 2021. Horizon Databook has segmented the Canada antibody drug conjugates market based on blood cancer, breast cancer, urothelial cancer & bladder cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is expected to witness significant growth over the forecast period, owing to factors such as high cancer prevalence and major research activities. Key antibody drug products, such as Kadcyla, Adcetris, & Mylotarg, have been available in the market and have been effectively used for the treatment of various cancers.
In September 2020, Polivy was approved by Canadian Health authorities for treatment of diffuse large B-cell lymphoma. Various other ADCs are currently under review or in clinical development. The approval for new ADCs is expected to drive the market over the forecast period.
As per the World Cancer Research Fund, Canada has one of the highest cancer prevalence in the world, with approximately 334 cases per 100,000 individuals. Cancers such as lung cancer comprised ~13% of all cancer cases in Canada in 2020.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada antibody drug conjugates market size, by application, 2018-2030 (US$M)
Canada Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
